Amiloride, a
diuretic used in the treatment of
hypertension and
congestive heart failure, and
2-guanidine-4-methylquinazoline (GMQ) are
guanidine compounds that modulate
acid-sensing ion channels. Both compounds have demonstrated affinity for a variety of
membrane proteins, including members of the Cys-loop family of
ligand-gated ion channels, such as the heteromeric
GABA-A αβγ receptors. The actions of these
guanidine compounds on the homomeric
GABA-A ρ1 receptor remains unclear, especially in light of how many
GABA-A αβγ receptor modulators have different effects in the
GABA-A ρ1 receptors. We sought to characterize the influence of
amiloride and GMQ on the human
GABA-A ρ1 receptors using whole-cell patch-clamp electrophysiology. The
diuretic amiloride potentiated the human
GABA-A ρ1
GABA-mediated current, whereas GMQ antagonized the receptor. Furthermore, a
GABA-A second transmembrane domain site, the intersubunit site, responsible for allosteric modulation in the heteromeric
GABA-A receptors mediated
amiloride's positive allosteric actions. In contrast, the mutation did not remove GMQ antagonism but only changed the
guanidine compound's potency within the human
GABA-A ρ1 receptor. Through modeling and introduction of point mutations, we propose that the
GABA-A ρ1 intersubunit site plays a role in mediating the allosteric effects of
amiloride and GMQ.